Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target

11Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges.

Cite

CITATION STYLE

APA

Rotella, D., Siekierka, J., & Bhanot, P. (2021, February 3). Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target. Frontiers in Microbiology. Frontiers Media S.A. https://doi.org/10.3389/fmicb.2020.610408

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free